Ozeki Y, Masaki T, Kamata A, Miyamoto S, Yoshida Y, Okamoto M, et al
Only 5% to 10% of patients discontinue treatment due to side effects
Phase II Clinical Trials: Efinopegdutide (Merck/Johnson & Johnson/Hanmi Hanma), VK2735 (Viking Therapeutics), BGM0504 (BrightGene), Pemvidutide (Altimmune/Spitfire Pharma), AMG133 (Amgen), Dapiglutide (Zealand Pharma), etc
The availability of both weekly injectable and daily oral formulations further broadens its reach across diverse patient and prescriber segments
Oral GLP-1 Weight Loss Medication Side Effects Oral GLP-1s share similar side effects with injectablesmainly nausea, diarrhea, constipation, and abdominal discomfort
However, the cost and utilization of these powerful drugs require careful planning